5 6 0 1 5

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊



更多详情 >>



作者优惠计划

Favored Author Program


很高兴为我们作者提供一种切实的方法以支持开放获取,并鼓励教师和研究人员通过开放获取模式,尽可能广泛地传播他们的作品。


作者优惠计划的成员将获得:


文章发表费(APC) 10% 的折扣


这 10% 的折扣从您加入 “作者优惠计划” 之时开始,并将适用于之后提交的所有论文



更多详情 >>



 

视频

CYP2D6  polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study

 

Authors Wickramage I, Tennekoon KH, Ariyaratne MAY, Hewage AS, Sundralingam T

Received 3 November 2016

Accepted for publication 2 February 2017

Published 6 March 2017 Volume 2017:9 Pages 111—120

DOI https://doi.org/10.2147/BCTT.S126557

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Professor Pranela Rameshwar

Introduction and aims: Tamoxifen is an adjuvant drug effective in treating hormone ­receptor – positive breast cancer. However, 30%–50% of patients relapse and many develop adverse effects, such as hot flashes and fatty liver. Allelic variations altering the activity of cytochrome P450-2D6 enzyme affect response to tamoxifen by modulating metabolism of tamoxifen into its pharmacologically active metabolite endoxifen. Although association between CYP2D6  polymorphisms and recurrence of breast cancer in patients on tamoxifen had been reported, little evidence exists on association between these polymorphisms and adverse effects to tamoxifen. This study explored the association between CYP2D6  polymorphisms and tamoxifen effects, hitherto not studied in Sri Lanka.
Methods:
 A retrospective preliminary study was carried out on 24 breast cancer patients on tamoxifen for minimally 3 months attending National Cancer Institute, Maharagama, Sri Lanka. They were not on CYP2D6-inhibiting drugs, chemotherapy or other endocrine therapy, and had no conditions that could occur as adverse effects to tamoxifen before starting the therapy. Their blood samples were collected, DNA was extracted and genotyped using SNaPshot Multiplex sequencing based single-nucleotide polymorphism (SNP) assay.

Results: SNP/allele frequencies detected: 1846G>A (confirmatory of *4 null allele)=8.3%; 2549delA (confirmatory of *3 null allele)=50%; 100C>T (suggestive of *10 reduced functional allele, in addition to other alleles)=0%; combination of 2988G>A, -1584C and 2850C>T (strongly suggestive of *41 or other reduced functional allele)=4.8%. Occurrence of heterozygous 2988G>A SNP with -1584C and 2850C>T was significantly higher among those with ultrasound-diagnosed fatty liver following the commencement of tamoxifen therapy (=0.029). Adverse effects occurred at a significantly higher frequency among postmenopausal women (=0.041). Three patients who developed recurrence of breast cancer had no association with SNPs tested.
Conclusions: CYP2D6  SNP combination 2988G>A, -1584C and 2850C>T, strongly suggestive of *41 reduced functional allele, is likely to be useful in predicting occurrence of adverse effect fatty liver in breast cancer patients on tamoxifen, thereby alternative treatment can be considered and lifestyle modifications implemented. Larger sample studies are recommended with the measurement of tamoxifen and metabolite levels. Alternative therapy should be considered for postmenopausal patients.
Keywords: fatty-liver, 2988G>A, CYP2D6 *41, intermediate-metabolizer, SNP

 

摘要视频链接CYP2D6 polymorphisms and tamoxifen adverse effects